28 August 2017
Visiongain’s new report the Brain Monitoring Devices Market Forecast 2017-2027: Revenue Prospects by Device Type (Invasive & Non-Invasive), Product (EEG, CT, MRI, MEG, Others), Application (TBI, Epilepsy, Stroke, Others) and End-User (Hospitals, Neurological Centres, Other) indicates that the global brain monitoring devices market will see over $9bn in revenue in 2017.
The lead analyst of the report said:
“The brain monitoring devices market is expected to grow at a healthy CAGR over the study forecast period. The key drivers supporting the growth of the market are increasing prevalence and incidence neurological disorders such as epilepsy, stroke, and traumatic brain injuries. In addition, the increasing geriatric population, increasing awareness of brain function monitoring, and technological advancements in monitoring devices is further expected to fuel market growth. However, factors such as high cost of devices, lack of skilled labour force, and under penetration of diagnostics procedures in developing countries are likely to hinder the growth of the market in the near future.”
The 155-page report contains 119 tables, charts and graphs that add visual analysis in order to explain developing trends within the brain monitoring devices market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading brain monitoring devices submarkets, segmented by device type, with forecasts for invasive and non-invasive brain monitoring devices. The market is also segmented by product, and includes forecasts for Electroencephalogram (EEG), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Magnetoencephalogram (MEG) and other brain monitoring devices. The report also includes forecasts for the applications of brain monitoring devices, including traumatic brain injuries (TBI), epilepsy, stroke and others. In addition, the report also contains forecasts for the brain monitoring devices market by end-user, including hospitals neurological centres and others.
The 155-page report offers market forecasts and analysis for 12 national markets, as well as the rest of the world, market. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the field in brain monitoring devices technology.
The Brain Monitoring Devices Market Forecast 2017-2027: Revenue Prospects by Device Type (Invasive & Non-Invasive), Product (EEG, CT, MRI, MEG, Others), Application (TBI, Epilepsy, Stroke, Others) and End-User (Hospitals, Neurological Centres, Other) report will be of value to anyone who wants to better understand the brain monitoring devices market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the brain monitoring devices industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth